leukoencephalopathy


Also found in: Medical, Wikipedia.
Translations

leu·ko·en·ceph·a·lop·a·thy

n. leucoencefalopatía, cambios progresivos en la materia blanca del cerebro encontrados en niños que padecen de leucemia y que se asocian a lesiones producidas por radiación y quimoterapia.

leukoencephalopathy

n leucoencefalo-patía; progressive multifocal — leucoencefalopatía multifocal progresiva
References in periodicals archive ?
market in February 2005 following reports that associated its use with cases of multifocal leukoencephalopathy.
amp; DUBLIN -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that the European Commission (EC) has approved the inclusion of anti-JC virus (JCV) antibody status as an additional factor to aid in stratifying patients at risk for developing progressive multifocal leukoencephalopathy (PML) in the Summary of Product Characteristics (SmPC) for TYSABRI([R]) (natalizumab) in the European Union (EU).
The side effect is a brain virus called progressive multifocal leukoencephalopathy (PML).
On Thursday, the company said a study of Tysabri showed the drug did not increase the risk of a virus called JCV, which is the underlying cause of a rare viral infection called progressive multifocal leukoencephalopathy, or PML.
PHILADELPHIA -- Migraine patients have an increased risk for subclinical brain lesions that sometimes resemble lesions found in patients with multiple sclerosis or cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, according to a population-based MRI study conducted in the Netherlands.
This provides an opportunity to identify patients at lower or higher risk for the development of progressive multifocal leukoencephalopathy (PML), an infrequent but serious brain infection.
The cases of the disease, progressive multifocal leukoencephalopathy, were confirmed last week, Biogen said in a regulatory filing.
Prospects for the eventual return of the unique multiple sclerosis treatment natalizumab (Tysabri) became more uncertain when a second case of progressive multifocal leukoencephalopathy was confirmed in a patient who had been treated with the drug for over 2 years, in combination with interferon beta-1a.
Food and Drug Administration and the European Medicines Agency for approval to update TYSABRI([R]) (natalizumab) labeling to include anti-JC virus antibody status as an additional factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML) in TYSABRI patients.
Cases of the infection, progressive multifocal leukoencephalopathy, were generally found in patients who had risk factors, including treatment with immunosuppressant drugs, Roche said.
The FDA granted approval for reintroduction based on the review of TYSABRI clinical trial data; revised labeling with enhanced safety warnings; and a risk management plan (TOUCH Prescribing Program) designed to inform physicians and patients of the benefits and risks of TYSABRI treatment and minimize potential risk of progressive multifocal leukoencephalopathy (PML).
JC virus is a recognized pathogen for progressive multifocal leukoencephalopathy, an incurable disease associated with demyelination of the CNS.